GPT-Rosalind vs Gemini 3.1 Pro: A domain specialist meets Google's long-context generalist

The September 11, 2026 announcement that GPT-Rosalind — Open​AI's purpose-built life-sciences reasoning model — is leaving research preview puts it into direct conversation with Goog​le's Gemini 3.1 Pro, the long-context frontier generalist that has been available in preview since February 19, 2026 at $2.00/$12.00 per 1M tokens. Both are frontier models with 1M-token context windows, but they were built around opposite bets: Rosalind on deep domain specialization for biology, drug discovery, and translational medicine; Gemini 3.1 Pro on multimodal breadth and extreme context. The price differential — $5.00/$25.00 against $2.00/$12.00 — is the smallest of any of Rosalind's matchups, which makes the specialization question sharper.

The two models, stated plainly

GPT-Rosalind was introduced on April 16, 2026 as Open​AI's first life-sciences model, named for Rosalind Franklin. It launched in research preview to U.S. trusted-access partners including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific, expanded in June with GPT-5.5-class agentic coding and tool use, and as of September 11, 2026 is out of research preview and available globally to eligible organizations through the trusted-access program, with billing at $5.00 per 1M input tokens, $0.50 cached input, and $25.00 per 1M output tokens effective October 5, 2026.

Gemini 3.1 Pro Preview is G​oogle's frontier reasoning model, focused on software engineering performance, agentic reliability, and token efficiency across complex workflows. It accepts text, image, speech, and video input with text output, serves a 1M-token context window with up to 65K output tokens, and lists at $2.00/$12.00 per 1M tokens for the first 200K input tokens, $4.00/$18.00 beyond. It has been available in preview since February 19, 2026.

The scoreboard

• Price — GPT-Rosalind $5.00 / $25.00 per 1M tokens (cached input $0.50), effective Oct 5. Gemini 3.1 Pro Preview $2.00 / $12.00 for ≤200K input, $4.00 / $18.00 above.

• AA Intelligence Index — Gemini 3.1 Pro Preview: 30.4, above average among 200-model class. GPT-Rosalind: not tracked on the general index.

• Input modalities — Gemini 3.1 Pro: text, image, speech, video. GPT-Rosalind: scientific file inputs (FASTA, PDFs, omics data) via ChatGPT, Codex, and API.

• Context window — Both 1M tokens. Gemini 3.1 Pro max output 65K; GPT-Rosalind output limit undisclosed but tool-heavy.

• Access — Gemini 3.1 Pro: API preview open to any account. GPT-Rosalind: trusted-access qualification review.

• Domain evals — GPT-Rosalind: BixBench leading, 6/11 LABBench2 wins over GPT-5.4, +53.7% GeneBench, +18.0% MedChemBench, +19.6% LabWorkBench (all vendor-reported). Gemini 3.1 Pro: GPQA Diamond 94.1, Humanity's Last Exam 47.0, no published life-sciences suite.

• Tool ecosystem — GPT-Rosalind: Life Sciences Research Plugin, 50+ tools and databases. Gemini 3.1 Pro: broad general tool use, no science-specific plugin stack.

The specialization premium

GPT-Rosalind's entire value proposition is that biological reasoning is a specialty, not a general capability. Its vendor-reported evaluations — leading BixBench performance, 6 of 11 LABBench2 wins over GPT-5.4, and per-token gains of 53.7% on GeneBench, 18.0% on MedChemBench, and 19.6% on LabWorkBench — all measure tasks that a generalist like Gemini 3.1 Pro was never specifically trained for: cloning-protocol design, RNA-function prediction, target prioritization, experimental planning. The partner evaluation from Dyno Therapeutics — exceeding the 95th percentile of human experts on RNA-sequence prediction — is the ceiling case, but with best-of-ten sampling priced in.

The honest counterweight is that every one of those numbers is O​penAI-reported. Gemini 3.1 Pro's strengths, by contrast, are independently verified: 94.1 GPQA Diamond, 47.0 Humanity's Last Exam, 82.0 Long-Context Recall, and a 30.4 AA Intelligence Index that Artificial Analysis places above average in its 200-model class. Its multimodal input — image, speech, and video alongside text — has no Rosalind equivalent. And at $2.00/$12.00 it costs 60% less than Rosalind on input, 52% less on output.

Where context wins

Gemini 3.1 Pro's genuine advantage is long-context reasoning over heterogeneous material. A full clinical trial package, a stack of PDFs and sequencing reports, a multi-modal grant document — Gemini 3.1 Pro holds a million tokens of mixed modality and reasons across it, with independent Long-Context Recall of 82.0. For teams whose scientific work is heavily literature- and document-based — reading, synthesizing, cross-referencing — the generalist's context handling and 65K output tokens may matter more than domain tuning. The specialization is real, but it is concentrated on molecular/sequence reasoning, not on document comprehension.

Where specialization wins

For the questions Gemini 3.1 Pro was never trained to answer — which target to prioritize, how a variant changes protein function, what protocol to run next — GPT-Rosalind is the only frontier model with evidence, vendor-reported as it is. The Life Sciences Research Plugin adds a practical edge: 50+ scientific tools and databases wired in as composable skills, usable in Codex, which is a concrete workflow advantage over a generalist model that would need the user to assemble those tools by hand. In a governed research environment that has cleared trusted-access qualification, Rosalind is the specialist pick.

Practical routing for both

Neither of these models requires a binary choice, and the routing layer is where they coexist cleanly. Gemini 3.1 Pro Preview is on OrcaRouter at list price — $2.00/$12.00 per 1M tokens, 0% markup, automatic failover — alongside 200+ other models, so a research pipeline can call it through the same O​penAI-compatible API it already uses. GPT-Rosalind is not yet on third-party routers; it needs the direct trusted-access application. But you can already build the sensible hybrid with the routing DSL: route document-heavy, multimodal, long-context synthesis to Gemini 3.1 Pro, and send the molecular-reasoning questions to the specialist endpoint. Automatic failover means neither leg stalls the pipeline. One API key, both strengths, and every vendor price cut passed through the day it happens.

Bottom line

GPT-Rosalind and Gemini 3.1 Pro are not competitors in the same lane. Gemini 3.1 Pro is the verified, multimodal, cheaper long-context generalist for the majority of research work — literature, documents, mixed-format data — with independent benchmarks to back it. GPT-Rosalind is the purpose-built specialist for the molecular core of biology — sequence, structure, target, protocol — with domain evidence that is real but vendor-reported, and an access gate that is real too. Choose Gemini 3.1 Pro if you need breadth, verification, and price. Choose Rosalind if you need the specialist edge on biological reasoning and your organization clears the trusted-access bar. The strongest setup is both — routed through one API, each doing what the other can't.